Investing.com - Tango Therapeutics (NASDAQ: TNGX) reported first quarter EPS of $-0.35, $0.04 worse than the analyst estimate of $-0.31. Revenue for the quarter came in at $6.47M versus the consensus estimate of $7.82M.
Tango Therapeutics's stock price closed at $7.85. It is down -36.74% in the last 3 months and up 114.48% in the last 12 months.
Tango Therapeutics saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Tango Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Tango Therapeutics's Financial Health score is "fair performance".
Check out Tango Therapeutics's recent earnings performance, and Tango Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar